63 results on '"Freifeld, Yuval"'
Search Results
2. Financial Considerations in the Management of Small Renal Masses
3. The role of malnutrition universal screening tool in predicting outcomes after radical cystectomy
4. Reply to Veerman et al. Comment on “Rosenzweig et al. Very Low Prostate PET/CT PSMA Uptake May Be Misleading in Staging Radical Prostatectomy Candidates. J. Pers. Med. 2022, 12, 410”
5. Association between early change in neutrophil‐to‐lymphocyte ratio after radical cystectomy and treatment outcomes
6. Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus
7. Very Low Prostate PET/CT PSMA Uptake May Be Misleading in Staging Radical Prostatectomy Candidates
8. Nutritional Status Impairment Due to Neoadjuvant Chemotherapy Predicts Post-Radical Cystectomy Complications
9. MP11-14 VERY LOW PROSTATE PET CT PSMA EXPRESSION MAY BE MISLEADING IN STAGING PROSTATECTOMY CANDIDATES
10. Neoadjuvant SABR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombus—Safety Lead-in Results of a Phase 2 Trial
11. Predictive model for systemic recurrence following cisplatin-based neoadjuvant chemotherapy and radical nephroureterectomy for high risk upper tract urothelial carcinoma
12. Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma
13. Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy?
14. Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy
15. Overcoming sociodemographic factors in the care of patients with testicular cancer at a safety net hospital
16. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database
17. MP73-05 BCG-UNRESPONSIVE NMIBC, COMPARISON OF 2 ND -LINE INTRAVESICAL INSTILLATION THERAPY
18. PD39-11 IMPROVED SURVIVAL AFTER CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA IN THE CONTEMPORARY IMMUNOTHERAPY ERA: A NATIONAL POPULATION-BASED ANALYSIS
19. Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle
20. MP82-10 PREDICTIVE MODEL FOR SYSTEMIC RECURRENCE FOLLOWING CISPLATIN-BASED NEOADJUVANT CHEMOTHERAPY AND RADICAL NEPHROURETERECTOMY FOR UPPER TRACT UROTHELIAL CARCINOMA
21. MP14-12 STEREOTACTIC ABLATIVE RADIATION THERAPY (SABR) FOR TREATMENT OF RENAL CELL CARCINOMA (RCC) WITH INFERIOR VENA CAVA TUMOR THROMBUS (IVC-TT)
22. Overcoming sociodemographic factors in the care of testicular cancer patients at a safety net hospital.
23. Rational Approaches to Treatment Duration with Immunotherapy in Metastatic Renal Cell Carcinoma
24. Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma
25. Impact of Hospital Case Volume on Outcomes Following Radical Nephrectomy and Inferior Vena Cava Thrombectomy
26. Preoperative predictive model and nomogram for disease recurrence following radical nephroureterectomy for high grade upper tract urothelial carcinoma
27. Evaluation of Hematuria in a Large Public Health Care System
28. Site of extranodal metastasis impacts survival in patients with testicular germ cell tumors
29. Magnetic Resonance Imaging–guided In-bore and Magnetic Resonance Imaging-transrectal Ultrasound Fusion Targeted Prostate Biopsies: An Adjusted Comparison of Clinically Significant Prostate Cancer Detection Rate
30. Is Malignant Germ-Cell Tumor Associated With Cowden Syndrome?
31. Pathologic response and surgical outcomes in patients undergoing nephrectomy after receipt of immune checkpoint inhibitors for renal cell carcinoma.
32. PD03-09 SAFETY AND FEASIBILITY OF NEPHRECTOMY AFTER RECEIPT OF IMMUNE CHECKPOINT INHIBITORS FOR RENAL CELL CARCINOMA
33. MP30-09 PROSPECTIVELY ASSIGNED POSITIVE CONTRAST ENHANCEMENT SCORE DETECTS MORE CLINICALLY SIGNIFICANT PROSTATE CANCER IN MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING USING PI-RADS V2
34. PD62-11 PATHOLOGIC STAGE AS A SURROGATE FOR ONCOLOGIC OUTCOMES AFTER RECEIPT OF NEOADJUVANT CHEMOTHERAPY FOR HIGH-GRADE UPPER TRACT UROTHELIAL CARCINOMA
35. MP49-06 NATIONWIDE PATTERNS OF CARE FOR STAGE II NON-SEMINOMATOUS GERM CELL TUMOR: RPLND AND CHEMOTHERAPY UTILIZATION
36. Diagnostic Performance of Prospectively Assigned Likert Scale Scores to Determine Extraprostatic Extension and Seminal Vesicle Invasion With Multiparametric MRI of the Prostate
37. Safety and feasibility of nephrectomy after receipt of immune checkpoint inhibitors for renal cell carcinoma.
38. Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study
39. Stereotactic Body Radiation Therapy for Renal Cell Carcinoma with Inferior Vena Cava Thrombus – Initial Experience Report and Literature Review
40. Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy
41. Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study
42. A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma
43. Effect of blue-light cystoscopy on contemporary performance of urine cytology
44. Comparison of Partial and Radical Laparascopic Nephrectomy: Perioperative and Oncologic Outcomes for Clinical T2 Renal Cell Carcinoma
45. Imaging for Screening and Surveillance of Patients with Hereditary Forms of Renal Cell Carcinoma
46. Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes
47. Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma
48. Therapeutic strategies for upper tract urothelial carcinoma
49. PD23-04 ADDED VALUE OF SYSTEMATIC BIOPSIES IN MEN WITH ABNORMAL MULTIPARAMETRIC MRI UNDERGOING MRI-TRUS FUSION PROSTATE BIOPSY
50. LBA28 SAFETY LEAD-IN OF A PHASE II TRIAL OF NEO-ADJUVANT SABR FOR IVC TUMOR THROMBUS IN RCC
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.